Sequence-specific interactions of minor groove binders with restriction fragments of cDNAs for H tau 40 protein and MAP kinase 2. A qualitative and quantitative footprinting study.
A series of DNA minor groove binders comprising netropsin, distamycin, the bisquaternary ammonium heterocycles SN 6999 and SN 6570, cis-diammine platinum(II)-bridged bis-netropsin, cis-diammine platinum(II)-bridged bis-distamycin and bis-glycine-linked bis-distamycin were investigated for sequence-specific interactions. The oligonucleotides used were the 154 base pair HindIII-RsaI restriction fragment of cDNA of h tau 40 protein and the 113 base pair NcoI-PvuII restriction fragment of cDNA of MAP kinase 2. Both proteins are believed to be involved in the pathology of Alzheimer's disease. For all these ligands, binding sites were localised at positions 1134-1139 (5'AATCTT3'), 1152-1156 (5'ATATT3') and 1178-1194 (5'TTTCAATCTTTTTATTT3') for the former and 720-726 (5'TATTCTT3'), 751-771 (5'AATTGTATAATAAATTTAAAA3') and 781-785 (5'TATTT3') for the latter. The AT-preference of ligand binding was obvious and footprint titration experiments were applied to estimate binding constants (Ka) for each individual binding site mentioned above. The binding strength decreases in the order netropsin > distamycin > SN 6999 approximately SN 6570>platinum-bridged netropsin or distamycin approximately bis-glycine-bridged distamycin and was found independently of the binding sites examined. GC-base pairs interspersed in short AT-tracts reduced the Ka-values by as much as two orders of magnitudes. The dependence of extended bidentate as well as of monodentate binding of netropsin and distamycin derivatives on the length of AT-stretches has been discussed.
Institute of Molecular Biotechnology, Beutenbergstrasse 11, D-07745 Jena, Germany. lkittler@imb-jena.de
L
L
Kittler
B C
BC
Baguley
G
G
Löber
M J
MJ
Waring
D002945:Cisplatin / Q000494:pharmacology; D018983:DNA Footprinting; D004262:DNA Restriction Enzymes; D018076:DNA, Complementary / Q000378:metabolism*; D003720:Densitometry; D004214:Distamycins / Q000378:metabolism / Q000494:pharmacology*; D008024:Ligands; D008565:Membrane Proteins / Q000235:genetics*; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics*; D009429:Netropsin / Q000378:metabolism / Q000494:pharmacology*; D009690:Nucleic Acid Conformation / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology*; D011806:Quinolinium Compounds / Q000378:metabolism / Q000494:pharmacology*; D016875:tau Proteins
D002945:Cisplatin; D004262:DNA Restriction Enzymes; D018076:DNA, Complementary; D004214:Distamycins; D008024:Ligands; D008565:Membrane Proteins; D019950:Mitogen-Activated Protein Kinase 1; D009429:Netropsin; D011725:Pyridines; D011806:Quinolinium Compounds; C404786:SN 6570; C030000:stallimycin; C062476:SN 6999; C054369:MAPT protein, human; D016875:tau Proteins